Company profile
Eagle Pharmaceuticals, Inc.
OTC: EGRX · Healthcare · Drug Manufacturers - Specialty & Generic
#243 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ —GM —SS 53
v0.1 · 5/100 weight · pillars only
↑ operating margin, return on assets · ↓ market scale, disclosure history
Methodology →Revenue TTM
$257.6M
Rev growth YoY (TTM)
-5.4%
Net income (FY)
$35.6M
Employees
135
as of 2026-08-22
Market cap
$2.0M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$316.6M$316.6M2022
Net income$35.6M$35.6M2022
Operating income$81.0M$81.0M2022
Total assets$406.2M$406.2M2022
Liabilities$172.6M$172.6M2022
Equity$233.6M$233.6M2022
Revenue trend
FY2015 – FY2022 · USD
FY15
FY16
FY17
FY18
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2022
By product
Product72%
Big Bag (or Belrapzo)11%
Ryanodex10%
Bendeka4%
Other Product2%
By geography
Not disclosed.
The read
What is Eagle Pharmaceuticals, Inc.’s revenue?
Eagle Pharmaceuticals, Inc. booked $316.6M in FY2022 revenue, growing 85% year over year — faster than most Healthcare companies we track, at a 11.3% net margin.
Peers · Healthcare
Fulgent Genetics, Inc.68BDocGo Inc.44DKnight Therapeutics Inc.77B+CorMedix Inc.75B+Health Catalyst, Inc.56CPROCEPT BioRobotics Corporation63CNeighbors
Bergen →Key facts
CEOMichael Graves
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersWoodcliff Lake, NJ
ExchangeOTC: EGRX
Employees135
IPO date2014-02-12
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.